1.
Expert Rev Hematol
; 14(1): 1-5, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: covidwho-962283
Asunto(s)
COVID-19/epidemiología , Neoplasias Hematológicas/terapia , Trasplante de Células Madre Hematopoyéticas , Pandemias , SARS-CoV-2 , Centros de Atención Terciaria , Adulto , Aloinjertos , Autoinjertos , Femenino , Neoplasias Hematológicas/epidemiología , Humanos , Masculino , Persona de Mediana Edad , España
2.
Br J Haematol
; 191(3): 386-389, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: covidwho-697165
RESUMEN
The COVID-19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment who represent a vulnerable population for SARS-CoV-2 infection. Aggressive lymphoid neoplasms, such as diffuse large B cell lymphoma and high-grade B cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed to minimise the risk of SARS-CoV-2 infection while continuing haematological treatment. In this report, we analyse the management of front-line therapy in 18 patients during the COVID-19 outbreak, as well as the results of the implemented measures in their outcome.